Results 91 to 100 of about 164,596 (212)

Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity [PDF]

, 2017
Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea.
Bhatta, Puspanjali, Borse, Vikrant, Dhukhwa, Asmita, FH Al Aameri, Raheem, Ghosh, Sumana, Kaur, Tejbeer, Lowy, Michelle, Mukherjea, Debashree, Ramkumar, Vickram, Rybak, Leonard P, Sheehan, Kelly, Sheth, Sandeep, Tupal, Srinivasan   +12 more
core   +2 more sources

Role of Autophagy in Cisplatin Resistance of Retinoblastoma Y79 Cells and Its Mechanism

Zhongliu Fangzhi Yanjiu, 2018
Objective To investigate the role of autophagy in cisplatin resistance of retinoblastoma Y79 cells and its mechanism. Methods The IC50 of cells was detected by CCK-8 assay. Y79 cells were randomly divided into control group, Cisplatin group and cisplatin
LIU Ying, SU Jie, WANG Linhong
doaj   +1 more source

Cisplatin-Based Chemotherapy for Pulmonary Metastasized Germ Cell Tumors of the Testis - Be Aware of Acute Respiratory Distress Syndrome [PDF]

, 2009
Background: Cisplatin-based combination chemotherapy is regarded as standard of care for patients with advanced germ cell tumors. In patients with lung metastases and a high tumor load, an association between induction chemotherapy and the development of
Baumann, Anja, Boeck, Stefan, Gallmeier, Eike, Hausmann, Andreas, Metzeler, Klaus H., Parhofer, Klaus G., Stemmler, Hans-Joachim   +6 more
core   +1 more source

Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma

Molecular & Cellular Oncology
Cisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence.
Ankit P. Jain, Vivek Ghose, Srijon Munshi, Firdous A. Bhat, Gourav Dey, Vishalakshi Nanjappa   +5 more
doaj   +1 more source

Reduced expression of bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance

European Journal of Medical Research, 2010
Resistance to cisplatin in the course of chemotherapy contributes to the poor prognosis of small cell lung cancer (SCLC). B cell lymphoma-2 is the founding member of a large family of proteins that either promote or inhibit apoptosis.
Biagosch J, Huber RM, Bergner A
doaj   +1 more source

Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins [PDF]

, 2017
The development of drug resistance continues to be a dominant hindrance toward curative cancer treatment. Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein or MDR1) is a well-known resistance ...
Assaraf, Yehuda G., Colotti, Gianni, Fazi, Francesco, Genovese, Ilaria, Ilari, Andrea   +4 more
core   +1 more source

Knockdown of TOP2A reverses cisplatin resistance in ovarian cancer by inhibiting EMT via ferroptosis mediated by the TP53/GPX4/SLC7A11 axis

Frontiers in Immunology
IntroductionCisplatin resistance is a major challenge in ovarian cancer therapy, particularly for high-grade serous ovarian cancer (HGSOC). DNA topoisomerase IIα (TOP2A) relates to cancer drug resistance, yet its role and molecular mechanisms in ovarian ...
Xinyue Liu, Xinyue Liu, Junxia Wang, Yangyu Liu, Yan Han, Zhichao Qin, Yu Wang, Shanxiang Gao, Xinghua Li, Yuping Suo   +9 more
doaj   +1 more source

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells

Taiwanese Journal of Obstetrics & Gynecology, 2011
Objective: There is a need to develop alternative therapeutic strategies to overcome cisplatin-associated resistance in patients with ovarian cancer. Histone deacetylation (HDAC) associated with inactivation of genes has been implicated in the epigenetic
Yen-Ying Ma, Hao Lin, Jau-Sung Moh, Kuang-Den Chen, I-Wen Wang, Yu-Che Ou, Ying-Shu You, Chia-Chi Lung   +7 more
doaj   +1 more source

SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line [PDF]

, 2001
The therapeutic potential of cisplatin, one of the most active and widely used anticancer drugs, is severely limited by the occurrence of cellular resistance.
Boersma, A.W.M. (Anton), Brandsma, J.A. (Jourica), Brouwer, J. (Jaap), Burger, H. (Herman), Dulk, H. (Hans) den, Nooter, K. (Kees), Schenk, P.W. (Paul), Stoter, G. (Gerrit)   +7 more
core  

Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma

Frontiers in Pharmacology
Oral squamous cell carcinoma (OSCC) is a crucial public health problem, accounting for approximately 2% of all cancers globally and 90% of oral malignancies over the world.
Rongkun Chen, Rongkun Chen, Shuyu Zhu, Ruoyu Zhao, Ruoyu Zhao, Wang Liu, Wang Liu, Luxin Jin, Luxin Jin, Xiaobin Ren, Xiaobin Ren, Hongbing He   +11 more
doaj   +1 more source